- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Epidemiology and Impact of Hidradenitis Suppurativa
An expert on hidradenitis suppurativa discusses the epidemiology of the disease and its profound impact on patients’ lives.
EP: 1.Signs and Symptoms of Hidradenitis Suppurativa (HS)
EP: 2.Epidemiology and Impact of Hidradenitis Suppurativa
EP: 3.The Pathophysiology of Hidradenitis Suppurativa
EP: 4.Differential Diagnosis When Considering Hidradenitis Suppurativa in a Patient
EP: 5.Overview of the Hurley Staging System for Hidradenitis Suppurativa
EP: 6.Comorbidities and Coordinating Care Between Specialists in Hidradenitis Suppurativa
EP: 7.Hidradenitis Suppurativa: Addressing the Psychosocial Impact and Hospitalization Rate
EP: 8.The Impact of Hidradenitis Suppurativa on Families
EP: 9.Hidradenitis Suppurativa (HS): Staging Considerations and Unmet Needs
EP: 10.The Role of Treatment Guidelines for HS
EP: 11.Biologic Therapies for Hidradenitis Suppurativa
EP: 12.Recent Data on Bimekizumab for Hidradenitis Suppurativa
EP: 13.Ongoing Research in Hidradenitis Suppurativa
EP: 14.Managing Pain in Patients with Hidradenitis Suppurativa
EP: 15.The Role of Surgery in Hidradenitis Suppurativa
EP: 16.Optimizing Multidisciplinary Care of Patients with Hidradenitis Suppurativa
Video content above is prompted by the following questions:
- What are some of the important epidemiological figures that are associated with hidradenitis suppurativa (HS) and how can clinicians incorporate these into their practices?
- How can this disease negatively impact patients’ lives?
Hidradenitis Suppurativa Disproportionately Affects Black, Female Patients
September 25th 2024A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.
Read More
Dermatologist Dissects Rosacea Diagnosis Challenges Among Patients of Color
September 17th 2024Hilary Baldwin, MD, FAAD, highlighted diagnostic complexities and shared treatment strategies for rosacea in patients with darker skin tones at the Skin of Color Update in New York City last Friday.
Read More
Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials
September 17th 2024Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.
Read More
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis
September 16th 2024The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Read More
